Evidence map›Paper›PMID 40531728›Full record

GuidelineJornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia2025

Brazilian guidelines for the pharmacological treatment of pulmonary embolism. Official document of the Brazilian Thoracic Association based on the GRADE methodology.

Veronica Moreira Amado, Caio Júlio César Dos Santos Fernandes, William Salibe-Filho, Marcelo Basso Gazzana, Ana Thereza Rocha, Hugo Hyung Bok Yoo, Wanderley Marques Bernardo, Suzana Tanni

Abstract readPractice Guideline
In one paragraph

Guideline in Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Is PESI a reliable tool for predicting early mortality in acute pulmonary embolism? Real-life evidence from a single-center study.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Veronica Moreira Amado. Universidade de Brasília - UnB - Brasília (DF) Brasil.ORCID http://orcid.org/0000-0003-4253-4935
Caio Júlio César Dos Santos Fernandes. Grupo de Circulação Pulmonar, Departamento de Cardiopneumologia, Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo (SP) Brasil.ORCID http://orcid.org/0000-0002-4912-021X
William Salibe-Filho. Grupo de Circulação Pulmonar, Departamento de Cardiopneumologia, Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo (SP) Brasil.ORCID http://orcid.org/0000-0002-2199-9525
Marcelo Basso Gazzana. Universidade Federal do Rio Grande do Sul - UFRGS - Porto Alegre (RS) Brasil.ORCID http://orcid.org/0000-0003-0086-1890
Ana Thereza Rocha. Departamento de Saúde da Família, Universidade Federal da Bahia - UFBA - Salvador (BA) Brasil.ORCID http://orcid.org/0000-0002-5321-2598
Hugo Hyung Bok Yoo. Faculdade de Medicina de Botucatu, Universidade Estadual Paulista - UNESP - Botucatu (SP) Brasil.ORCID http://orcid.org/0000-0003-3226-2788
Wanderley Marques Bernardo. Programa de Diretrizes, Associação Médica Brasileira, São Paulo (SP) Brasil.ORCID http://orcid.org/0000-0002-8597-5207
Suzana Tanni. Faculdade de Medicina de Botucatu, Universidade Estadual Paulista - UNESP - Botucatu (SP) Brasil.ORCID http://orcid.org/0000-0002-2587-2759

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Venous thromboembolism (VTE) is the third most common acute cardiovascular syndrome after acute myocardial infarction and stroke. In recent years, there has been an increase in the incidence of VTE, related to population aging and common comorbidities in the elderly, including chronic cardiorespiratory disease and cancer. On the other hand, disease-related mortality, particularly for pulmonary embolism (PE), shows a decreasing trend, which can be explained by improvements in diagnostic imaging, advances in available therapies, and greater adherence to patient management protocols. The guidelines presented here provide recommendations for the pharmacological treatment of PE in Brazil, on the basis of scientific evidence and with a focus on common practical issues. Six Patient, Intervention, Comparison, and Outcome questions were developed by a group of experts on the topic. Systematic reviews of randomized clinical trials were conducted for each question, with meta-analyses being performed when possible. The level of evidence and strength of recommendation were defined in accordance with the Grading of Recommendations Assessment, Development, and Evaluation approach. With these guidelines, we expect to provide relevant, up-to-date information on the pharmacological treatment of PE.

Indexed as

AnticoagulantsPulmonary EmbolismBrazilHumansRandomized Controlled Trials as TopicAnticoagulants

Identifiers

PMID40531728
PMCPMC12401105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.